CK Life Sciences Int'l., (Holdings) Inc.

SEHK:775 Stock Report

Market Cap: HK$4.3b

CK Life Sciences Int'l. (Holdings) Past Earnings Performance

Past criteria checks 0/6

CK Life Sciences Int'l. (Holdings)'s earnings have been declining at an average annual rate of -22.4%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 1.2% per year. CK Life Sciences Int'l. (Holdings)'s return on equity is 0.4%, and it has net margins of 0.3%.

Key information

-22.4%

Earnings growth rate

-22.4%

EPS growth rate

Biotechs Industry Growth11.0%
Revenue growth rate1.2%
Return on equity0.4%
Net Margin0.3%
Last Earnings Update31 Dec 2023

Recent past performance updates

CK Life Sciences Int'l. (Holdings)'s (HKG:775) Anemic Earnings Might Be Worse Than You Think

Apr 25
CK Life Sciences Int'l. (Holdings)'s (HKG:775) Anemic Earnings Might Be Worse Than You Think

Recent updates

There's No Escaping CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Muted Revenues Despite A 32% Share Price Rise

May 03
There's No Escaping CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Muted Revenues Despite A 32% Share Price Rise

CK Life Sciences Int'l. (Holdings)'s (HKG:775) Anemic Earnings Might Be Worse Than You Think

Apr 25
CK Life Sciences Int'l. (Holdings)'s (HKG:775) Anemic Earnings Might Be Worse Than You Think

CK Life Sciences Int'l. (Holdings) (HKG:775) Use Of Debt Could Be Considered Risky

Mar 26
CK Life Sciences Int'l. (Holdings) (HKG:775) Use Of Debt Could Be Considered Risky

Here's Why CK Life Sciences Int'l. (Holdings) (HKG:775) Can Manage Its Debt Responsibly

Sep 27
Here's Why CK Life Sciences Int'l. (Holdings) (HKG:775) Can Manage Its Debt Responsibly

Does CK Life Sciences Int'l. (Holdings) (HKG:775) Have A Healthy Balance Sheet?

Sep 16
Does CK Life Sciences Int'l. (Holdings) (HKG:775) Have A Healthy Balance Sheet?

Estimating The Intrinsic Value Of CK Life Sciences Int'l., (Holdings) Inc. (HKG:775)

Aug 21
Estimating The Intrinsic Value Of CK Life Sciences Int'l., (Holdings) Inc. (HKG:775)

These 4 Measures Indicate That CK Life Sciences Int'l. (Holdings) (HKG:775) Is Using Debt Extensively

Apr 14
These 4 Measures Indicate That CK Life Sciences Int'l. (Holdings) (HKG:775) Is Using Debt Extensively

CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) Delivered A Weaker ROE Than Its Industry

Mar 18
CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) Delivered A Weaker ROE Than Its Industry

If You Had Bought CK Life Sciences Int'l. (Holdings) (HKG:775) Shares Five Years Ago You'd Have Earned 45% Returns

Feb 01
If You Had Bought CK Life Sciences Int'l. (Holdings) (HKG:775) Shares Five Years Ago You'd Have Earned 45% Returns

What Kind Of Shareholders Hold The Majority In CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Shares?

Jan 04
What Kind Of Shareholders Hold The Majority In CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Shares?

CK Life Sciences Int'l. (Holdings) (HKG:775) Has A Somewhat Strained Balance Sheet

Dec 09
CK Life Sciences Int'l. (Holdings) (HKG:775) Has A Somewhat Strained Balance Sheet

We Wouldn't Rely On CK Life Sciences Int'l. (Holdings)'s (HKG:775) Statutory Earnings As A Guide

Nov 18
We Wouldn't Rely On CK Life Sciences Int'l. (Holdings)'s (HKG:775) Statutory Earnings As A Guide

Revenue & Expenses Breakdown
Beta

How CK Life Sciences Int'l. (Holdings) makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SEHK:775 Revenue, expenses and earnings (HKD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 235,323175930
30 Sep 235,318615750
30 Jun 235,3141045560
31 Mar 235,2951185460
31 Dec 225,2761325370
30 Sep 225,2901305430
30 Jun 225,3051285500
31 Mar 225,3531455610
31 Dec 215,4021635720
30 Sep 215,3021505720
30 Jun 215,2011385730
31 Mar 215,0721325570
31 Dec 204,9431255410
30 Sep 204,8461125400
30 Jun 204,750985400
31 Mar 204,8591405460
31 Dec 194,9671825520
30 Sep 195,1282235460
30 Jun 195,2882635410
31 Mar 195,2612635330
31 Dec 185,2332635250
30 Sep 185,0772615170
30 Jun 184,9202595090
31 Mar 184,8072595080
31 Dec 174,6932585070
30 Sep 174,6742475130
30 Jun 174,6552365180
31 Mar 174,7622445200
31 Dec 164,8692535220
30 Sep 164,9332405160
30 Jun 164,9982285100
31 Mar 164,9592235010
31 Dec 154,9192194920
30 Sep 154,9532574950
30 Jun 154,9872964980
31 Mar 154,9702804980
31 Dec 144,9542644980
30 Sep 144,9302504950
30 Jun 144,9072364910
31 Mar 144,9392324910
31 Dec 134,9712294900
30 Sep 134,8512154800
30 Jun 134,7302014700

Quality Earnings: 775 has a large one-off gain of HK$133.6M impacting its last 12 months of financial results to 31st December, 2023.

Growing Profit Margin: 775's current net profit margins (0.3%) are lower than last year (2.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 775's earnings have declined by 22.4% per year over the past 5 years.

Accelerating Growth: 775's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 775 had negative earnings growth (-86.9%) over the past year, making it difficult to compare to the Biotechs industry average (22.1%).


Return on Equity

High ROE: 775's Return on Equity (0.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.